TWI786742B - 吡啶酮類化合物及其製備方法和應用 - Google Patents
吡啶酮類化合物及其製備方法和應用 Download PDFInfo
- Publication number
- TWI786742B TWI786742B TW110127160A TW110127160A TWI786742B TW I786742 B TWI786742 B TW I786742B TW 110127160 A TW110127160 A TW 110127160A TW 110127160 A TW110127160 A TW 110127160A TW I786742 B TWI786742 B TW I786742B
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- compound
- substituted
- group
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010719751 | 2020-07-23 | ||
CN202010719751.4 | 2020-07-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202210460A TW202210460A (zh) | 2022-03-16 |
TWI786742B true TWI786742B (zh) | 2022-12-11 |
Family
ID=79728529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110127160A TWI786742B (zh) | 2020-07-23 | 2021-07-23 | 吡啶酮類化合物及其製備方法和應用 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN115803316A (fr) |
TW (1) | TWI786742B (fr) |
WO (1) | WO2022017524A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200626576A (en) * | 2004-09-15 | 2006-08-01 | Novartis Ag | Bicyclic amides as kinase inhibitors |
US20110034461A1 (en) * | 2008-02-05 | 2011-02-10 | Sanofi-Aventis | Sf5 derivatives as par1 inhibitors, production thereof, and use as medicaments |
CN105051027A (zh) * | 2013-03-15 | 2015-11-11 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物 |
CN107074768A (zh) * | 2014-09-10 | 2017-08-18 | 葛兰素史克知识产权发展有限公司 | 作为转染重排(ret)激酶抑制剂的吡啶酮衍生物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2587207A1 (fr) * | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | Agonistes des recepteurs de la niacine, compositions contenant ces composes et methodes de traitement |
ES2691227T3 (es) * | 2014-10-16 | 2018-11-26 | Bayer Pharma Aktiengesellschaft | Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfoximina |
-
2021
- 2021-07-23 WO PCT/CN2021/108286 patent/WO2022017524A1/fr active Application Filing
- 2021-07-23 CN CN202180049358.1A patent/CN115803316A/zh active Pending
- 2021-07-23 TW TW110127160A patent/TWI786742B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200626576A (en) * | 2004-09-15 | 2006-08-01 | Novartis Ag | Bicyclic amides as kinase inhibitors |
US20110034461A1 (en) * | 2008-02-05 | 2011-02-10 | Sanofi-Aventis | Sf5 derivatives as par1 inhibitors, production thereof, and use as medicaments |
CN105051027A (zh) * | 2013-03-15 | 2015-11-11 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物 |
CN107074768A (zh) * | 2014-09-10 | 2017-08-18 | 葛兰素史克知识产权发展有限公司 | 作为转染重排(ret)激酶抑制剂的吡啶酮衍生物 |
Also Published As
Publication number | Publication date |
---|---|
WO2022017524A1 (fr) | 2022-01-27 |
TW202210460A (zh) | 2022-03-16 |
CN115803316A (zh) | 2023-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6782255B2 (ja) | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 | |
CN102459187B (zh) | Janus激酶抑制化合物和方法 | |
TW202128691A (zh) | Kras 突變蛋白抑制劑 | |
JP7046940B2 (ja) | 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物 | |
JP6139789B2 (ja) | 縮合複素環化合物、その調製方法、医薬組成物及びその使用 | |
JP7331212B2 (ja) | フェニル-2-ヒドロキシ-アセチルアミノ-2-メチル-フェニル化合物 | |
CA3088927A1 (fr) | Derive de biaryle, procede de preparation et usage pharmaceutique associes | |
WO2018225093A1 (fr) | Composés chimiques utilisés comme inhibiteurs de la voie atf4 | |
TW200806675A (en) | Heterobicyclic thiophene compounds and methods of use | |
CA2908098A1 (fr) | Inhibiteurs mk2 et utilisations associees | |
JP2023535746A (ja) | Cdk7キナーゼ阻害剤として使用される化合物およびその適用 | |
EP3470409A1 (fr) | Composes dérivés de benzotriazole a et b amide non satures utilises comme inhibiteurs de tgf-br1 | |
EP2949647A1 (fr) | Composé d'aminopyrimidine phényle deutérié et composition pharmaceutique le contenant | |
JP2022502444A (ja) | 3−アザビシクロ[3,1,1]ヘプタン誘導体及びこれを含む薬学的組成物 | |
TW201103894A (en) | 4-substituted pyridazinone compound and p2x7 receptor inhibitor | |
CN113164475A (zh) | Dyrk1a的大环抑制剂 | |
EP4074710A1 (fr) | Composé de pyrazolo[1,5-a]pyridine, son procédé de préparation et son utilisation | |
TW202043232A (zh) | Pde9抑制劑及其用途 | |
TW202035408A (zh) | 三環janus 激酶1 抑制劑及其組合物和方法 | |
JP2021501215A (ja) | アミノ置換窒素含有縮合環化合物、その調製方法及び使用 | |
CN110028507A (zh) | 具有trk激酶抑制活性化合物、制备方法、组合物及用途 | |
TW200936579A (en) | Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor | |
KR20230043885A (ko) | 트리시클릭 헤테로사이클 | |
WO2021099832A2 (fr) | Composés antagonistes des récepteurs de l'adénosine | |
CN110804059B (zh) | 氨基甲酸酯类化合物、药物组合物及其应用 |